iinews – Der mobile Newsdienst

« | »

Sepsis Diagnostics Market to hit USD 613.9 Million by 2023, at a CAGR of 9.1%


The Global Sepsis Diagnostics Market was valued at USD 367.9 Million in 2017 and is expected to reach USD 613.9 Million by 2023, at a CAGR of 9.1% during the forecast period.

The Research report provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the Sepsis Diagnostics Market, along with revenue estimates & forecasts and market share analysis.

Increasing prevalence of sepsis across the globe, increasing geriatric population, growing government initiatives for creating sepsis awareness, and high incidence of hospital-acquired infections are expected to drive the demand for sepsis diagnosis during the study period.

Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155

Sepsis Diagnostics Market segmentation:

· Based on Technology

· Based on Product

· Based on Pathogen

· Based on Method

· Based on Test Type

· Based on End Users

· Based on Regions

The Major Players Opearting in the Sepsis Diagnostics Market:

Key players in the Sepsis Diagnostics Market include bioMérieux (France), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), Abbott (US), Roche (Switzerland), Danaher (US), Becton, Dickinson, and Company (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), CytoSorbents (US), and Mitsubishi Chemical Europe (Germany).

bioMérieux (France) is the leading player in the global Sepsis Diagnostics Market. The company has a strong global presence with strong distribution channels to serve markets in North America, Europe, Oceania, Africa, and Asia Pacific.

The company has been focusing new product development and product approvals in the field of sepsis diagnostics. For instance, in April 2017, bioMérieux received FDA approval for its BacT/ALERT VIRTUO fully automated blood culture system. In July 2016, bioMérieux received FDA approval for the expanded use of its VIDAS BRAHMS PCT (Procalcitonin) assay. Through this, it introduced innovative products in the market, which enabled it to garner a higher market share.

Geographical Detailed Analysis for Sepsis Diagnostics Market:

Asia Pacific is the largest regional segment in the Sepsis Diagnostics Market followed by Europe, Asia, and the Rest of the World (Row).

Asia Pacific is expected register highest growth during the forecast period, owing to the growing prevalence of sepsis in APAC countries, rising focus of global players in this region, developing healthcare infrastructure, and rising government support for sepsis-related research.

Read More in Detailed (Sepsis Diagnostics):


Posted by on 27. Juni 2019.


Categories: Bilder, Vermischtes

0 Responses

You must be logged in to post a comment.

« | »

Neueste Beiträge